The U.S. Food and Drug Administration (FDA) announced a pilot program to expedite regulatory review of generic drugs that are both tested and manufactured domestically with U.S.-sourced active pharmaceutical ingredients. This initiative aligns with broader government efforts to reshore pharmaceutical manufacturing, aiming to decrease reliance on foreign supply chains and enhance drug availability and quality assurance in the United States.